The data obtained from the international literature, corresponding to that of the World Health Organization, report an incidence of lymphedema in the world of approximately 300 million cases (about one person in every 20). Almost half of lymphedema is of primary origin, characterized by a congenital Lymphangioadenodysplastic basis, that is due to a malformation and consequent malfunction of lymph nodes and / or lymphatic vessels. Another 70 million are of parasitic origin (the most frequent forms are represented by the infestation of Filaria Bancrofti), particularly present in tropical and subtropical areas (India, Brazil, South-Africa). Another 50 million are post-surgical and, especially, secondary to the treatment of breast cancer. The other 30 million are essentially caused by functional problems of overload of the lymphatic circulation (particularly, as a result of deep phlebothrombosis of the lower limb, liver failure, nephrotic syndrome, and arteriovenous fistulas).
In particular, with regards to secondary lymphedema, the incidence of secondary lymphedema of the upper limb in women undergoing mastectomy or quadrantectomy with axillary lymphadenectomy is best estimated to be equal to 20-25% of patients, up to 35-40% when associated to radiotherapy. With the sentinel lymph node technique, the incidence of secondary lymphedema varies from 3% to 22%. With regards to lymphedema of the lower secondary to the treatment of gynecological and urological tumors, the incidence varies from 5% to 30%. Given the high incidence of secondary lymphedema, it is worth emphasizing the importance of prevention of lymphatic pathology, both in terms of early diagnosis and timely treatment. The gender most often affected is the female sex and the most affected age corresponds to the third to fourth decade of life. The incidence of lymphangitis, clinically more or less manifest, as a complication of lymph stasis, is very high (practically in almost all cases), to the point of requiring a protracted antibiotic treatment, both for therapeutic and prophylactic purposes.
Lymphedema represents a not rare clinical picture characterized by the slowing or blockage of the lymphatic circulation of the affected limb or limbs, with a progressively worsening evolution and the appearance of recurrent acute lymphangitic complications, mostly of erysipeloid nature, responsible for a further and rapid increase in volume and consistency of edema. Although pathogenetic details are still an open question, the general principles of the pathophysiology of lymphedema are well known. On the one hand, the central disturbance may be represented by a low-output failure of the lymphatic system: in other words, there is a general reduction in lymphatic transport. An alteration of this type may be caused by congenital lymphatic dysplasia – primary lymphedema – or by anatomical obliteration, such as that resulting from a radical surgical resection (for example, in the case of axillary lymph node, iliac-inguinal, or retroperitoneal dissection), following repeated lymphangitis with lymphangiosclerosis or as a consequence of severe functional impairment (for example, lymphangiospasm, paralysis and valvular insufficiency) – secondary lymphedema.
However, the common denominator is the fact that lymphatic transport falls below the capacity needed to manage the daily microvascular filtrate load, comprising plasma proteins and cells, which normally enter the interstitium from the bloodstream.
On the other hand, a high output failure of the lymphatic circulation occurs when a normal or increased transport capacity is overwhelmed by an excessive load of capillary blood filtrate: for example, in cirrhosis of the liver (ascites), nephrotic syndrome (anasarca) and deep venous insufficiency of the lower limbs (post-thrombophlebitic syndrome).
Failure to control lymphedema can lead to repeated infections (dermatolymphangioadenitis – DLA), progressive pachydermic cutaneous trophic skin changes and, in rare cases, even to the development of a lymphangiosarcoma, which is a highly lethal pathology (Stewart-Treves syndrome).
Lymphedema is generally divided into primary or congenital and acquired or secondary.
Primary lymphedemas are further categorized as congenital (connatal) that is, already present at birth, or as a praecox manifestation if they appear before 35 years of age, or tardive, if they occur after 35 years of age. Among the connatal forms, the sporadic forms are distinct from those heriditary-familial forms that, for the most part, can be framed in more or less complex malformation syndromes, related to specific genetic alterations. For the identification of the type of dysplasia that underlies the different forms of congenital lymphedema, the classification of C.Papendieck is followed: LAD I (lymphangiodysplasia – dysplasia of the lymphatic vessels), LAD II (lymphadenodysplasia – dysplasia of the lymph nodes), LAAD (lymphangio-adeno-dysplasia – dysplasia of lymphatics and lymph nodes). The term dysplasia includes: agenesis, hypoplasia, hyperplasia, fibrosis, lymphangiomatosis, hamartomatous, and valvular insufficiency. Secondary lymphedema can be calssified as post-surgical, post-actinic, post-traumatic, post-lymphagitic, and parasitic.
Classification of lymphedema:
Primary or Congenital
Secondary or acquired
This staging includes both primary and secondary lymphedema, already clinically manifest lymphedema, and also subclinical lymphedema (stage IA, in which lymphoscintigraphy allows early detection of an initial lymphatic circulatory alteration), and the clinical evolution of the disease, regardless of the nature of the lymphedema. The staging of lymphedema is based on clinical and diagnostic-instrumental criteria: extent of edema, clinical course of the disease during the day, and with the variation of the decubitus, number and extent of lymphangitic complications, consistency of edema, and skin changes related to the disease. Finally, it is possible to evaluate the severity of the clinical picture on the basis of the volumetric difference between the limbs, defining as minimal (<20% increase in volume), moderate (increase from 20 to 40%) and severe (> 40% increase). This staging in the above table was adapted by us starting from 2009, standardizing it with classification in three stages from the International Society of Lymphology
In most patients, on the basis of the medical history and objective physical examination, one can easily diagnose lymphedema: edema generally of thickened consistency (depending on the greater or lesser fibrosclerotic tissue component), absence of fovea sign, even in the precocious stages of the disease, presence of the Stemmer sign (inability to pinch the skin at the base of the 2nd toe), dystrophic cutaneous lesions (post-lymphangitic sequelae, hyperkeratosis, lymphatic verrucosis, lymphorrhea, chylorrhea), and frequent dermato-lympangioadenitic complications (DLA). Moreover, the evaluation of the lymph nodes is useful, to highlight the association of acute or chronic lymphadenopathy. In the more complex forms of angiodysplasia, characterized by a condition of arterio-venous hyperstomy (Mayall syndrome) or by congenital macro- and micro- arteriovenous fistulas (Klippel-Trénaunay or Klippel-Trénaunay-Servelle syndrome), the clinical picture can be characterized by: gigantism with elongation of the limb, more or less marked dysmorphism of the foot, “Port wine” or geographical map angiomas, hyperhidrosis of the sole of the foot. There are, however, spurious forms, even more difficult to diagnose for the prevalent lymphedematous component. Moreover, in some cases, there is the presence of overlapping conditions, such as pathological obesity, venous insufficiency, more or less evident trauma, and recurrent infections, which can complicate the clinical picture. Furthermore, when considering the origin of a uni- or bilateral lymphedema of the extremities, especially in adults, it is also necessary to consider the possibility of a tumor. For all these reasons, before embarking on the treatment of lymphedema, a complete and integrated diagnostic evaluation is absolutely essential. The association of other pathological conditions, such as congestive heart failure, arterial hypertension, and cerebrovascular diseases, including stroke, can in turn influence the therapeutic process. If the diagnosis of lymphedema is not clear or if there is a need, even for prognostic considerations, of a better diagnostic definition of the clinical picture, a specialized lymphological consultation is advisable, directing the patient to a specialized lymphology center.
Lymphoscintigraphy is the first choice exam for the diagnostic definition of edema, to confirm its lymphostatic nature, to identify the cause (from obstruction or reflux), to evaluate the extent of the disease (dermal back flow), the major or minor impairment of the deep lymphatic circulation with respect to the superficial one, and the drainage through the lymph node stations. The study of both the superficial and deep lymphatic circulation is very useful, through the appropriate injection of the tracer in the specific drainage sites of the two systems. The examination is not invasive, easily repeatable, can be performed even in neonatal age. It also allows the identification of stage IA lymph stasis, still not clinically manifest, thus playing a fundamental role in the prevention of secondary lymphedema. It is also useful, finally, for the study during the follow-up of the different therapeutic methods of lymphedema and, in particular, of lymphatic microsurgery techniques.
Lymphography is still an extremely useful investigation for the study of the complex congenital or acquired pathologies of chyliferous vessels, of the cisterna chyli, and of the thoracic duct. It is more modernly performed in the operating room, under local anesthesia, and with preparation of the lymphatic vessels by microsurgical technique. Ultrasound, CT, and MRI are useful diagnostic tools for the definition of complex syndromes in which angiodysplasia and lymphedema pathologies are associated, as well as for the study of the possible obstructive nature of lymphedema, secondary to oncological disease. The Lymphangio-MRI, in particular, performed with the digital fat-subtraction method, can provide important information in advanced obstructive pictures, in which the lymphatic pathways are dilated and filled with lymph. Indispensable is the study of venous circulation using Echo-Color-Doppler (an investigation constantly used in the evaluation of an edematous limb). Phleboscintigraphy and Phlebography may also be performed (if necessary on the basis of the Echo-Doppler exam). Even the study of the arterial circulation can be indispensable in panangiodysplasia clinical pictures with associated lymphedema. In these cases, in addition to the Echo-Color-Doppler exam, digital arteriographic study may be useful. Micro-lymphography with Indocyanine Green fluorescent dye (PDE Test) and the Houdack-Mc Master Lymphochromic Test (with Blue Patent Violet dye, BPV) are now available to provide very useful information for the most correct surgical approach for lymphedema.
Diagnosis s of lymphoedema-main investigations
Complementary investigations (intra-operative)
Additional investigations (second line, for cases of lymphedema associated with venous and / or arterial pathology)
The treatment of peripheral lymphedema is divided into medical-physical-rehabilitative treatment and surgical methods.
Lymphedema therapy
Non-surgical treatment
Pharmacological therapy
Surgical treatment
INFORMATION REGARDING THE PROCESSING OF PERSONAL DATA EU 679/2016
The user’s personal data are used by Lymphaticsurgery, which is the data controller, in compliance with the principles of protection of personal data established by the GDPR 2016/679 Regulation.
METHOD AND PURPOSE OF DATA PROCESSING
1) We inform you that the data will be processed with the support of the following means:
a) Paper (registration forms, order forms, etc.)
b) IT (management software, accounting, etc.)
c) Telematics
with the following purposes:
– provision of the services requested by the Customer or available on portals managed by (personnel selection, newsletters, information material, free material) as well as the conclusion of the contract of which the interested party is a party;
– administrative and accounting purposes related to service contracts;
Any refusal to allow the processing of data will make it impossible to use the service requested by the user.
LEGAL BASIS
2) The provision of data is mandatory for all that is required by legal and contractual obligations and therefore any refusal to provide them in whole or in part may result in the impossibility of providing the requested services.
The company processes the user’s optional data on the basis of consent, i.e. through the explicit approval of this privacy policy and in relation to the methods and purposes described below.
CATEGORIES OF RECIPIENTS
3) Without prejudice to communications made in fulfillment of legal and contractual obligations, all data collected and processed may be communicated exclusively for the purposes specified above to the following categories of interested parties:
– Commercial consultants;
– Accounting and administrative;
– Suppliers.
– Customers (patients)
STORAGE PERIOD
4) The data required for contractual and accounting purposes are kept for the time necessary to carry out the commercial and accounting relationship. The data of those who do not purchase or use products / services, despite having had a previous contact with company representatives, will be immediately deleted or treated anonymously, where their conservation is not otherwise justified, unless it has been validly acquired. the informed consent of the interested parties relating to a subsequent commercial promotion or market research activity. Data retention will comply with the laws in force on the matter.
RIGHTS OF THE INTERESTED PARTY
5) Pursuant to European Regulation 679/2016 (GDPR) and national legislation, the interested party may, according to the methods and within the limits established by current legislation, exercise the following rights:
– request confirmation of the existence of personal data concerning him (right of access);
– know its origin;
– receive intelligible communication;
– have information about the logic, methods and purposes of the processing;
– request the updating, rectification, integration, cancellation, transformation into anonymous form, blocking of data processed in violation of the law, including those no longer necessary for the pursuit of the purposes for which they were collected;
– in cases of consent-based processing, receive their data provided to the owner, in a structured and readable form by a data processor and in a format commonly used by an electronic device;
– the right to lodge a complaint with the supervisory authority.
Requests should be addressed to the Data Controller.
6) The data controller of your personal data is Lymphaticsurgery – Via Assarotti 46 / 1- 16132 Genova (GE), Italy E-mail: info@campisiandpartners.com, genovamedicalcentersrl@pec.it Tel./Fax: +39 010 83 93 755
This privacy policy may undergo changes over time – also related to the possible entry into force of new sector regulations, the updating or provision of new services or technological innovations – for which the user / visitor is invited to consult periodically at the privacy button at the bottom of www.lymphaticsurgery.it. The information is printable and can be saved.